CU20120169A7 - Compuestos pirimidinílicos como inhibidores de la cinasa atr - Google Patents
Compuestos pirimidinílicos como inhibidores de la cinasa atrInfo
- Publication number
- CU20120169A7 CU20120169A7 CU2012000169A CU20120169A CU20120169A7 CU 20120169 A7 CU20120169 A7 CU 20120169A7 CU 2012000169 A CU2012000169 A CU 2012000169A CU 20120169 A CU20120169 A CU 20120169A CU 20120169 A7 CU20120169 A7 CU 20120169A7
- Authority
- CU
- Cuba
- Prior art keywords
- atr
- inhibitors
- cinasa
- pyrimidinyl compounds
- pyrimidinyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Se proporcionan compuestos pirimidinílicos de fórmula(I), o sales farmacéuticamente aceptables de estos, procesos para su preparación,composiciones farmacéuticas que los contienen útiles en el tratamiento de una enfermedad proliferativa, tal como el cáncer, y particularmente en en una enfermedad mediada por ataxia-telangiectasia mutada e inhibidores de la proteína cinasa relacionada con RAD-3, denominada habitualmente ATR.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35371310P | 2010-06-11 | 2010-06-11 | |
PCT/GB2011/051074 WO2011154737A1 (en) | 2010-06-11 | 2011-06-09 | Morpholino pyrimidines and their use in therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
CU20120169A7 true CU20120169A7 (es) | 2014-02-28 |
CU24109B1 CU24109B1 (es) | 2015-07-30 |
Family
ID=44168987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU20120169A CU24109B1 (es) | 2010-06-11 | 2011-09-06 | Compuestos pirimidinílicos como inhibidores de la cinasa atr |
Country Status (38)
Country | Link |
---|---|
US (5) | US8252802B2 (es) |
EP (1) | EP2579877B1 (es) |
JP (1) | JP5721821B2 (es) |
KR (1) | KR101820996B1 (es) |
CN (1) | CN103068391B (es) |
AR (1) | AR081859A1 (es) |
AU (1) | AU2011263491B2 (es) |
BR (1) | BR112012031561B1 (es) |
CA (1) | CA2800203C (es) |
CL (1) | CL2012003503A1 (es) |
CO (1) | CO6640270A2 (es) |
CR (1) | CR20120628A (es) |
CU (1) | CU24109B1 (es) |
DK (1) | DK2579877T3 (es) |
DO (1) | DOP2012000310A (es) |
EA (1) | EA022087B1 (es) |
EC (1) | ECSP12012334A (es) |
ES (1) | ES2514325T3 (es) |
GT (1) | GT201200334A (es) |
HK (1) | HK1182019A1 (es) |
HR (1) | HRP20140953T1 (es) |
MX (1) | MX2012014477A (es) |
MY (1) | MY158193A (es) |
NI (1) | NI201200184A (es) |
NZ (1) | NZ604480A (es) |
PE (1) | PE20130306A1 (es) |
PL (1) | PL2579877T3 (es) |
PT (1) | PT2579877E (es) |
RS (1) | RS53566B1 (es) |
SA (1) | SA111320519B1 (es) |
SG (1) | SG185711A1 (es) |
SI (1) | SI2579877T1 (es) |
SM (1) | SMT201400146B (es) |
TW (1) | TWI526208B (es) |
UA (1) | UA109010C2 (es) |
UY (1) | UY33440A (es) |
WO (1) | WO2011154737A1 (es) |
ZA (1) | ZA201300255B (es) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SA111320519B1 (ar) * | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
JP6936007B2 (ja) | 2014-06-17 | 2021-09-15 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Chk1阻害剤とatr阻害剤との組み合わせを使用してがんを処置する方法 |
TWI656121B (zh) | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | 2-(嗎啉-4-基)-1,7-萘啶 |
MX2018003657A (es) | 2015-09-30 | 2018-04-30 | Vertex Pharma | Metodo para tratar cancer usando una combinacion de agentes que dañan el adn e inhibidores de proteina relacionada con ataxia telangiectasia y rad3 (atr). |
WO2018029117A1 (en) * | 2016-08-10 | 2018-02-15 | Rheinisch-Westfälische Technische Hochschule Aachen (RWTH) | New atr inhibitors for the use in cancer therapy |
AR110995A1 (es) | 2017-02-24 | 2019-05-22 | Bayer Ag | Combinación de inhibidores de quinasa atr con sal de radio-223 |
JOP20190197A1 (ar) | 2017-02-24 | 2019-08-22 | Bayer Pharma AG | مثبط كيناز ايه تي آر للاستخدام في طريقة لعلاج مرض فرط التكاثر |
WO2018153972A1 (en) | 2017-02-24 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Combination of atr kinase inhibitors and antiandrogens |
WO2018206547A1 (en) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and atr inhibitors |
US10421765B2 (en) | 2017-05-26 | 2019-09-24 | Board Of Regents, The University Of Texas System | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase |
PT3651768T (pt) | 2017-07-13 | 2024-03-20 | Univ Texas | Inibidores heterocíclicos da atr cinase |
US11690911B2 (en) | 2017-08-04 | 2023-07-04 | Bayer Aktiengesellschaft | Combination of ATR kinase inhibitors and PD-1/PD-L1 inhibitors |
EP3668839B1 (en) * | 2017-08-17 | 2023-04-12 | Board of Regents, The University of Texas System | Heterocyclic inhibitors of atr kinase |
CN111655688B (zh) * | 2017-09-08 | 2023-09-29 | 蓝谷制药有限责任公司 | 经取代的吡咯并吡啶类化合物作为atr抑制剂 |
EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
WO2019110586A1 (en) | 2017-12-08 | 2019-06-13 | Bayer Aktiengesellschaft | Predictive markers for atr kinase inhibitors |
GB201720989D0 (en) * | 2017-12-15 | 2018-01-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
JP7290651B2 (ja) * | 2018-02-07 | 2023-06-13 | ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド | Atr阻害剤及びその応用 |
EP3765008B1 (en) | 2018-03-16 | 2023-06-07 | Board of Regents, The University of Texas System | Heterocyclic inhibitors of atr kinase |
CA3116230A1 (en) | 2018-10-16 | 2020-04-23 | Bayer Aktiengesellschaft | Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds |
EP3899004A2 (en) * | 2018-12-18 | 2021-10-27 | Astrazeneca AB | Pharmaceutical process and intermediates |
KR20220008869A (ko) | 2019-05-14 | 2022-01-21 | 누베이션 바이오 인크. | 항암 핵 호르몬 수용체-표적화 화합물 |
GB201908536D0 (en) * | 2019-06-13 | 2019-07-31 | Glaxosmithkline Ip Dev Ltd | Compounds |
CN112142744A (zh) * | 2019-06-28 | 2020-12-29 | 上海瑛派药业有限公司 | 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用 |
CN114728957B (zh) * | 2019-08-06 | 2023-09-22 | 无锡智康弘义生物科技有限公司 | 一种atr抑制剂的晶型及其应用 |
US11952349B2 (en) | 2019-11-13 | 2024-04-09 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
WO2021098811A1 (zh) * | 2019-11-21 | 2021-05-27 | 江苏恒瑞医药股份有限公司 | 吡唑并杂芳基类衍生物、其制备方法及其在医药上的应用 |
CN112939966B (zh) * | 2019-12-10 | 2023-03-24 | 武汉光谷亚太医药研究院有限公司 | 嘧啶衍生物、其制备及应用 |
WO2021143821A1 (zh) * | 2020-01-17 | 2021-07-22 | 江苏恒瑞医药股份有限公司 | 稠合杂芳基类衍生物、其制备方法及其在医药上的应用 |
US20240150333A1 (en) * | 2020-03-20 | 2024-05-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Taf1 inhibitors |
CA3181382A1 (en) | 2020-05-11 | 2021-11-18 | Astrazeneca Ab | Atr inhibitors for the treatment of cancer |
EP4159734A1 (en) * | 2020-05-29 | 2023-04-05 | Shenzhen Lingfang Biotech Co., Ltd | Fluoropyrrolopyridine compound and application thereof |
CN111646985A (zh) * | 2020-06-01 | 2020-09-11 | 江苏集萃分子工程研究院有限公司 | 一种含嘧啶杂环抗肿瘤药物分子azd6738的合成方法 |
EP4171650A1 (en) | 2020-06-24 | 2023-05-03 | AstraZeneca UK Limited | Combination of antibody-drug conjugate and atr inhibitor |
IL299804A (en) * | 2020-07-13 | 2023-03-01 | Beijing Tide Pharmaceutical Co Ltd | Pyrazolopyrimidine compounds for use as ATR kinase inhibitors |
US20230399302A1 (en) * | 2020-10-29 | 2023-12-14 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Process for the preparation of heteroaryl-substituted sulfur(vi) compounds |
TW202304457A (zh) | 2021-03-22 | 2023-02-01 | 瑞典商阿斯特捷利康公司 | 配製物 |
US11834458B2 (en) | 2021-03-23 | 2023-12-05 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
EP4313057A1 (en) | 2021-03-26 | 2024-02-07 | Astrazeneca AB | Combination treatments for melanoma |
IT202100021863A1 (it) | 2021-08-13 | 2023-02-13 | Univ Degli Studi Milano | Morfolino pirimidine per l’uso nella prevenzione e/o nel trattamento di stati di ipereccitabilità neuronale |
WO2023039573A1 (en) * | 2021-09-10 | 2023-03-16 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Compounds for targeted degradation of taf1 |
CN116283960A (zh) * | 2021-12-21 | 2023-06-23 | 上海安诺达生物科技有限公司 | 取代的稠杂环化合物及其制备方法与应用 |
WO2023122723A1 (en) | 2021-12-23 | 2023-06-29 | The Broad Institute, Inc. | Panels and methods for diagnosing and treating lung cancer |
TW202339805A (zh) | 2021-12-28 | 2023-10-16 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及atr抑制劑之組合 |
TW202348252A (zh) | 2022-02-16 | 2023-12-16 | 英商梅迪繆思有限公司 | 用治療性結合分子治療癌症的組合療法 |
WO2023242302A1 (en) | 2022-06-15 | 2023-12-21 | Astrazeneca Ab | Combination therapy for treating cancer |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3922735A1 (de) | 1989-07-11 | 1991-01-24 | Hoechst Ag | Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide |
DE69837529T2 (de) | 1997-02-12 | 2007-07-26 | Electrophoretics Ltd., Cobham | Proteinmarker für lungenkrebs und deren verwendung |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
EP1154774B1 (en) | 1999-02-10 | 2005-06-22 | AstraZeneca AB | Quinazoline derivatives as angiogenesis inhibitors |
SK287401B6 (sk) | 1999-11-05 | 2010-09-07 | Astrazeneca Ab | Deriváty chinazolínu, spôsob ich prípravy, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie |
NZ520640A (en) | 2000-02-15 | 2005-04-29 | Upjohn Co | Pyrrole substituted 2-indolinone protein kinase inhibitors |
JP3649395B2 (ja) | 2000-04-27 | 2005-05-18 | 山之内製薬株式会社 | 縮合ヘテロアリール誘導体 |
EP1289952A1 (en) | 2000-05-31 | 2003-03-12 | AstraZeneca AB | Indole derivatives with vascular damaging activity |
UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
AU6623301A (en) | 2000-07-07 | 2002-01-21 | Angiogene Pharm Ltd | Colchinol derivatives as vascular damaging agents |
SK52003A3 (en) | 2000-07-07 | 2003-07-01 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors, method for their preparation and pharmaceutical composition comprising the same |
ATE340784T1 (de) | 2000-11-10 | 2006-10-15 | Hoffmann La Roche | Pyrimidinderivate und deren verwendung als neuropeptid-y-rezeptorliganden |
EP2316831B1 (en) | 2002-11-21 | 2013-03-06 | Novartis AG | 2-(morpholin-4-yl)pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer |
WO2005000404A2 (en) | 2003-05-29 | 2005-01-06 | Synta Pharmaceuticals, Corp. | Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss |
GB0415364D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
GB0415365D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
GB0415367D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
WO2007084413A2 (en) | 2004-07-14 | 2007-07-26 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
TW200628159A (en) | 2004-11-10 | 2006-08-16 | Synta Pharmaceuticals Corp | IL-12 modulatory compounds |
WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
WO2006124662A1 (en) | 2005-05-13 | 2006-11-23 | Synta Pharmaceuticals Corp. | Il-12 modulatory compounds |
EP1904504B1 (en) | 2005-05-20 | 2014-03-19 | MethylGene Inc. | Inhibitors of vegf receptor and hgf receptor signaling |
DE102005024494A1 (de) | 2005-05-27 | 2006-11-30 | Bayer Healthcare Ag | Verwendung von Cyanopyrimidinen |
CN101213192B (zh) | 2005-07-01 | 2012-06-06 | Irm责任有限公司 | 作为蛋白激酶抑制剂的嘧啶取代的苯并咪唑衍生物 |
US20100160255A1 (en) | 2005-07-29 | 2010-06-24 | Takeda Pharmaceutical Company Limited | Spiro-cyclic compound |
KR20080052630A (ko) | 2005-09-01 | 2008-06-11 | 어레이 바이오파마 인크. | Raf 억제제 화합물 및 그의 사용 방법 |
JP4531027B2 (ja) | 2005-09-29 | 2010-08-25 | 田辺三菱製薬株式会社 | 医薬組成物 |
JP2007091649A (ja) | 2005-09-29 | 2007-04-12 | Taisho Pharmaceut Co Ltd | ピリミジン誘導体及びその使用に関連する治療方法 |
AU2006297120B2 (en) | 2005-09-30 | 2011-05-19 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
SG151327A1 (en) | 2005-09-30 | 2009-04-30 | Vertex Pharmaceuticals Incopor | Deazapurines useful as inhibitors of janus kinases |
GB0520657D0 (en) | 2005-10-11 | 2005-11-16 | Ludwig Inst Cancer Res | Pharmaceutical compounds |
GB2431156A (en) | 2005-10-11 | 2007-04-18 | Piramed Ltd | 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase |
DK1945631T3 (da) | 2005-10-28 | 2012-10-22 | Astrazeneca Ab | 4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer |
US20100016319A1 (en) | 2005-11-29 | 2010-01-21 | Toray Industries, Inc. A Corporation Of Japan | Arylmethylene urea derivative and use thereof |
GB0525081D0 (en) | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
GB0525083D0 (en) | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
GB0525080D0 (en) | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
NL2000323C2 (nl) | 2005-12-20 | 2007-11-20 | Pfizer Ltd | Pyrimidine-derivaten. |
JP2009523161A (ja) * | 2006-01-11 | 2009-06-18 | アストラゼネカ アクチボラグ | モルホリノピリミジン誘導体と療法におけるその使用 |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
BRPI0706747A2 (pt) | 2006-01-30 | 2011-04-05 | Exelixis Inc | 4-aril-2-amino-pirimidinas ou 4-aril-2-aminoalquil-pirimidinas como moduladores jak-2 e composições farmacêuticas que os contenham |
BRPI0621509A2 (pt) | 2006-03-15 | 2011-12-13 | Csir | modulação da atividade de fosforil transferase de glutamina sintetase |
JP5243696B2 (ja) | 2006-03-17 | 2013-07-24 | 田辺三菱製薬株式会社 | ベンゼン誘導体 |
EP2003131A4 (en) | 2006-04-04 | 2009-12-16 | Taisho Pharmaceutical Co Ltd | AMINOPYRROLIDINE COMPOUND |
CA2648809A1 (en) | 2006-04-19 | 2007-11-01 | Novartis Ag | Indazole compounds and methods for inhibition of cdc7 |
WO2007126043A1 (ja) | 2006-04-27 | 2007-11-08 | Mitsubishi Tanabe Pharma Corporation | チアゾール環を含むカルボン酸誘導体の医薬用途 |
GB0610909D0 (en) | 2006-06-05 | 2006-07-12 | Merck Sharp & Dohme | Therapeutic treatment |
AU2007269540B2 (en) | 2006-07-05 | 2013-06-27 | Exelixis, Inc. | Methods of using IGF1R and Abl kinase modulators |
EP2057129A1 (en) | 2006-08-24 | 2009-05-13 | AstraZeneca AB | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
KR101435231B1 (ko) | 2006-08-24 | 2014-10-02 | 아스트라제네카 아베 | 증식성 질환의 치료에 유용한 모르폴리노 피리미딘 유도체 |
AU2007311480A1 (en) * | 2006-10-16 | 2008-04-24 | Forma Therapeutics, Inc. | Pyrido [2, 3-d] pyrimidines and their use as kinase inhibitors |
US20100256143A1 (en) | 2007-04-12 | 2010-10-07 | Stewart James Baker | Pharmaceutical compounds |
KR20100042643A (ko) | 2007-07-09 | 2010-04-26 | 아스트라제네카 아베 | 증식성 질환을 치료하기 위한 삼중치환된 피리미딘 유도체 |
US20110301122A1 (en) * | 2008-11-14 | 2011-12-08 | Bayer Schering Pharma Aktiengesellschaft | Heteroaromatic compounds for use as hif inhibitors |
UY32351A (es) * | 2008-12-22 | 2010-07-30 | Astrazeneca Ab | Compuestos de pirimidinil indol para uso como inhibidores de atr |
SA111320519B1 (ar) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
-
2011
- 2011-06-08 SA SA111320519A patent/SA111320519B1/ar unknown
- 2011-06-09 MY MYPI2012701121A patent/MY158193A/en unknown
- 2011-06-09 PT PT117254946T patent/PT2579877E/pt unknown
- 2011-06-09 US US13/156,684 patent/US8252802B2/en active Active
- 2011-06-09 KR KR1020137000590A patent/KR101820996B1/ko active IP Right Grant
- 2011-06-09 SG SG2012086112A patent/SG185711A1/en unknown
- 2011-06-09 DK DK11725494.6T patent/DK2579877T3/da active
- 2011-06-09 RS RSP20140534 patent/RS53566B1/en unknown
- 2011-06-09 JP JP2013513758A patent/JP5721821B2/ja active Active
- 2011-06-09 TW TW100120242A patent/TWI526208B/zh active
- 2011-06-09 CN CN201180039088.2A patent/CN103068391B/zh active Active
- 2011-06-09 SI SI201130280T patent/SI2579877T1/sl unknown
- 2011-06-09 AU AU2011263491A patent/AU2011263491B2/en active Active
- 2011-06-09 NZ NZ604480A patent/NZ604480A/en unknown
- 2011-06-09 EA EA201201680A patent/EA022087B1/ru not_active IP Right Cessation
- 2011-06-09 PL PL11725494T patent/PL2579877T3/pl unknown
- 2011-06-09 UY UY0001033440A patent/UY33440A/es not_active Application Discontinuation
- 2011-06-09 CA CA2800203A patent/CA2800203C/en active Active
- 2011-06-09 WO PCT/GB2011/051074 patent/WO2011154737A1/en active Application Filing
- 2011-06-09 MX MX2012014477A patent/MX2012014477A/es active IP Right Grant
- 2011-06-09 BR BR112012031561A patent/BR112012031561B1/pt active IP Right Grant
- 2011-06-09 PE PE2012002373A patent/PE20130306A1/es active IP Right Grant
- 2011-06-09 EP EP11725494.6A patent/EP2579877B1/en active Active
- 2011-06-09 ES ES11725494.6T patent/ES2514325T3/es active Active
- 2011-06-10 AR ARP110102022A patent/AR081859A1/es active IP Right Grant
- 2011-09-06 UA UAA201215028A patent/UA109010C2/en unknown
- 2011-09-06 CU CU20120169A patent/CU24109B1/es active IP Right Grant
-
2012
- 2012-07-02 US US13/540,057 patent/US8552004B2/en active Active
- 2012-12-11 CO CO12224297A patent/CO6640270A2/es active IP Right Grant
- 2012-12-11 EC ECSP12012334 patent/ECSP12012334A/es unknown
- 2012-12-11 CL CL2012003503A patent/CL2012003503A1/es unknown
- 2012-12-11 NI NI201200184A patent/NI201200184A/es unknown
- 2012-12-11 CR CR20120628A patent/CR20120628A/es unknown
- 2012-12-11 GT GT201200334A patent/GT201200334A/es unknown
- 2012-12-11 DO DO2012000310A patent/DOP2012000310A/es unknown
-
2013
- 2013-01-10 ZA ZA2013/00255A patent/ZA201300255B/en unknown
- 2013-08-12 HK HK13109418.0A patent/HK1182019A1/xx unknown
- 2013-09-18 US US14/030,134 patent/US8999997B2/en active Active
-
2014
- 2014-10-03 HR HRP20140953AT patent/HRP20140953T1/hr unknown
- 2014-10-09 SM SM201400146T patent/SMT201400146B/xx unknown
-
2015
- 2015-02-26 US US14/631,961 patent/US9155742B2/en active Active
- 2015-09-21 US US14/859,567 patent/US9421213B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU20120169A7 (es) | Compuestos pirimidinílicos como inhibidores de la cinasa atr | |
CY1124928T1 (el) | Αναστολεις πυραζολυλο κινοξαλινο κινασης | |
CY1124068T1 (el) | Στερεες μορφες ενος εκλεκτικου αναστολεα cdk4/6 | |
CL2017000469A1 (es) | Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1 | |
CY1120031T1 (el) | Αποπτωτικοι υποκινητες ν-ακυλοσουλφοναμιδης | |
NI201600018A (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b. | |
CL2014000746A1 (es) | Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer. | |
ECSP15048122A (es) | Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
CL2013002990A1 (es) | Compuestos derivados de imidazo[5,1-a]isoindol o sus sales, inhibidores de indolamina 2,3-dioxigenasa (ido); composicion farmaceutica, utiles para tratar la inmunosupresion asociada con una enfermedad infecciosa o cancer. | |
UY33539A (es) | Compuestos químicos alk | |
PE20150998A1 (es) | Inhibidores de histona demetilasas | |
UY35590A (es) | Nuevos compuestos para el tratamiento del cáncer | |
PE20151501A1 (es) | Inhibidores de prmt5 y sus usos | |
UY32351A (es) | Compuestos de pirimidinil indol para uso como inhibidores de atr | |
CO7160104A2 (es) | Inhibidores de virus de hepatitis c | |
ECSP109934A (es) | Compuesto - 946 | |
UA113215C2 (xx) | Похідні проліків (e)-n-метил-n-((3-метилбензофуран-2-іл)метил)-3-(7-оксо-5,6,7,8-тетрагідро-1,8-нафтиридин-3-іл)акриламіду | |
DOP2015000170A (es) | Compuestos químicos | |
CY1120133T1 (el) | Πυριδαζινονες ως αναστολεις ενζυμου daao | |
UY33305A (es) | Compuestos heterocíclicos inhibidores de DGAT1 | |
AR086876A1 (es) | Derivados heterociclicos de sulfonamida | |
NI201200162A (es) | Inhibidores de pirazolil quinoxalina cinasa | |
CU20100005A7 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
GT201500189A (es) | Inhibidores de autotaxina | |
CR20150584A (es) | Derivados de sulfamoilpirrolamiday su uso como medicamentos para el tratamiento de la hepatitis b |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant of patent |